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Background: Use of petroleum-based over the counter remedies such as Vicks VapoRub to alleviate symptoms of
rhinitis is common and can be effective, but carries under-appreciated risks of adverse side effects. In this case
report we highlight Exogenous Lipoid Pneumonia (ELP), an uncommon condition that results from accumulation of
exogenous lipids in the alveoli, as an adverse side effect of long-term Vicks VapoRub use.
Case presentation: We present the case of an 85-year-old female patient with ELP apparently due to continuous
application of Vicks VapoRub® to her nostrils to alleviate chronic rhinitis. She was diagnosed incidentally via chest
radiograph and computed tomography (CT) scan done as follow up to finding elevated C-reactive Protein during a
routine exam. The CT scan revealed a pulmonary consolidation in the lower lobe of the right lung with fat density
combined with low density areas associated with focal ground-glass opacities. The patient was advised to
discontinue use of petroleum-based products, and was prescribed intranasal corticosteroids for her rhinitis. Follow
up 2 years later showed that the lipid consolidation had diminished in size by approximately 10 %.
Conclusion: Physicians must be aware that ELP can develop as a result of long-term application of petroleum-
based oils and ointments to the nose and discourage such use of these products. Patients who have used
petroleum-based products in this way should be screened for ELP. CT scan is the best imaging modality for
establishing the diagnosis. The treatment of this condition is not well defined, but, as shown in this case, the size of
the lipid mass can decrease after use of petroleum based substances is discontinued.
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Exogenous lipoid pneumonia (ELP) is a rare condition
resulting from the aspiration or inhalation of fat-like mater-
ial of animal, vegetable or mineral origin [1]. The frequency
of ELP is difficult to establish, but autopsy series have re-
vealed frequencies of 1 to 2.5 % [2]. Forty four cases of ELP
were identified in a nationwide retrospective study in
France between 1981 and 1993 [3]. The principal factor for
ELP is the inhalation of inert, long-chain, saturated hydro-
carbons found in petroleum. Mineral oils and ointments* Correspondence: ivancherrez@gmail.com
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tating inhalation. Their presence in the pulmonary paren-
chyma causes a foreign body type of inflammatory reaction
[4, 5]. Most ELP cases result from the use of oil-based laxa-
tives for the treatment of constipation, or from nasal instil-
lation of oily products, including petroleum ointment
products such as Vaseline or Vicks VapoRub® [6], for relief
of chronic rhinopharyngeal diseases. Reported sources also
include lip balm/gloss [7]. Most of the patients who aspirate
these substances are elderly people who have difficulty
swallowing due to anatomic or functional issues, and who
have a history of topical application or ingestion of lipid
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toms such as cough, dyspnoea, chest pain, haemoptysis or
fever. They can also be asymptomatic, in which case ELP
may be identified as an incidental abnormality on radio-
logic imaging [5, 8]. On physical examination findings are
usually normal, although dullness on percussion, crackles,
wheezes or rhonchus may be found [4]. Laboratory find-
ings such as leucocytosis and increased erythrocyte sedi-
mentation rate can be found, especially when complicated
by an infection. In one study increased sedimentation rate
was observed in 61 % of ELP cases [3]. Pulmonary function
test results have shown a restrictive pattern in long-
standing disease [4]. Prominent radiologic abnormalities
have been found in the absence of symptoms or clinical
signs in many ELP cases [9].
High-resolution computed tomography (CT) is the best
imaging modality for establishing the diagnosis of ELP.
The most frequent findings are airspace consolidations,
ground-glass opacities, interlobular septal thickening, air-
space nodules (small poorly-defined centrilobular nodules),
and mass-like lesions [10]. The mass is typically irregular
or spiculated as a result of chronic inflammation and sec-
ondary fibrosis. Since its clinical and radiological presenta-
tions are nonspecific, ELP may mimic many other diseases,
including lung tumours [11]. The presence of fat in the
mass is a diagnostic feature of ELP [12]. The radiologic
manifestations of ELP can improve slowly over time, but
typically remain stable even if exposure to oils or fats is dis-
continued. ELP-related fibrosis and destruction of normal
lung architecture can result in cor-pulmonale [13].
Patients with rhinitis, a condition that usually presents
with nasal congestion, rhinorrhea, sneezing and itching,
often self-medicate, using over-the-counter decongestants
or folk remedies [14, 15]. One traditional folk remedy con-
sists of instilling medicated oil or ointment into the nose
and sniffing it. A variety of oil-based products have beenFig. 1 Thoracic CT at the first medical consultationused, including pure sesame oil [12] and mentholated
petroleum-based ointments such as Vicks VapoRub®.
Here we report the case of an patient in a routine
medical visit with history of rhinitis and mentholated
mineral ointment use who was found to have ELP.Case presentation
An 85-year-old Ecuadorian female self-referred for her
annual routine visit to family physician (Additional file 1:
Timeline Table). She had history of recurrent allergic
rhinitis events with nocturnal runny nose since childhood.
She revealed daily use of the over-the-counter mentholated
mineral ointment decongestant Vicks VapoRub® for ap-
proximately 50 years to ease her discomfort. She applied
this product to her chest, palms and feet, and aspirated it
through her nose.
The patient had no signs or symptoms of respiratory
disease at the time of the visit. Her physical examination
was unremarkable. Her medical history included type 2
diabetes mellitus and hypertension.
Laboratory findings demonstrated an increased CRP
(31.5 mg/L, reference value 0.0 – 5.0 mg/L). After obtaining
no relevant results, a follow up chest radiograph was or-
dered. It showed airspace consolidation as an irregular
mass-like-lesion in the right lower lobe. The patient contin-
ued to be asymptomatic despite the presence of this mass.
A thoracic computed tomographic (TCT) scan of the chest
was ordered. This showed a pulmonary consolidation of
5.0 × 4.5 cm in the posterior basal segment of the lower
lobe of the right lung, containing negative density regions
measuring between −130 HU and −61 HU, indicative of
intrapulmonary lipid (Fig. 1). Focal ground-glass opacities
were observed in the periphery and scattered ground glass
opacities bilaterally, which are suggestive of pneumonitis.
We recommended that the patient stop using Vicks
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rhinitis.
Twenty-six months after stopping daily mentholated
ointment application a follow-up TCT and CRP was or-
dered. The pulmonary consolidation described above
was still apparent, but the bilateral scattered ground
glass opacities had diminished and the size of the mass
had decreased by 0.5 cm in each dimension (4.5 ×
4.0 cm) (Fig. 2). CRP was in reference value (2.03 mg/L)
Discussion
Although ELP is an unusual cause of chronic lung disease,
it is an important consideration in the differential diagnosis
of several pulmonary syndromes because progression ap-
pears to be halted, or at least slowed, by stopping exposure
to the offending lipid substance. In our patient the pres-
ence of negative TCT density values in the mass implied
the presence of lipid. That fact, together with follow up
scan results, allowed us to rule out malignancy.
Several authors have suggested that negative density
values between −150 and −30 HU in areas of consolidation
are highly suggestive of intrapulmonary fat, and are con-
sistent with ELP, especially when associated with a history
of exposure to mineral oil or ointment. In order to prevent
a false positive interpretation, measurements should be
taken in the most hypodense part of the consolidation area,
free of any aerated parenchyma on the periphery or areas
of air bronchogram [5, 16, 17].
Systemic steroids have been used to slow the inflamma-
tory response associated with ELP, but their use is sup-
ported only by few anecdotal reports [18–21]. Because
inflammation will resolve spontaneously with cessation of
exposure in most cases, it seems steroids can be withheld
unless the lung injury is severe and progressive [8, 19].
ELP is often mild and does not appear to progress if use
of the causative agent is stopped. However, there are few
studies in which ELP masses are followed and measuredFig. 2 Thoracic CT 26 months after cessation of petroleum jellyafter patients have stopped using oil-based substances. In
one case involving a 38 year old woman with ELP, the mass
was reported to have diminished 2 years after stopping oil
ingestion, but the decrease was not quantified [22]. In the
present case we measured the ELP mass at the time of
diagnosis and 26 months after the patient discontinued use
of mentholated petroleum ointment, and found a 10 %
decrease in size. Prospective studies should be done to
determine the average rate at which ELP masses decrease
after use of the causative agent is stopped.
The best treatment for ELP is prevention. However, the
fact that ELP is a potential risk associated with chronic
use of lipid substances is not always appreciated, even by
physicians. A recent review about rhinitis in geriatric
populations said that use of oil substances in the nose is
generally safe and can be used adjunctively with other
treatment [23]. Mineral oil and ointment products are
sold without prescription, and no information is provided
for consumers or clinicians on possible hazards, especially
among people at risk of aspiration, including the elderly
and people with gastroesophageal reflux, dysphagia, nasal
congestion or neurologic disease. Mentholated ointments
have been shown to be cilio-toxic and mildly proinflam-
matory, increasing mucus secretion while decreasing
mucus clearance [24]. This gives the sensation of
increased airflow and therefore relief of symptoms, but in
fact there is no improvement in airflow or decrease in
nasal resistance with the use of these products [25].
Health professionals need to be aware of the risks and
discourage the uncontrolled use of mineral oil and oint-
ment, especially for the very young and the elderly [26].
Conclusion
We suspect that our patient developed ELP due to ex-
cessive use of Vicks VapoRub® for chronic rhinitis. ELP
was confirmed by TCT, which was ordered because of
elevated CRP findings. Physicians need to be aware of
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mineral oil and ointment. The ability to recognize radio-
logical manifestations of ELP can help establish an early
diagnosis and start timely intervention.
The main intervention is discontinuing use of lipid
substances. In the reported case, we found a 10 % de-
crease in size of the ELP mass 26 months after the pa-
tient stopped using Vicks VapoRub®. Further studies
should be done to determine average rates at which
ELP-related masses decrease after use of lipid substances
is stopped.
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